256 related articles for article (PubMed ID: 30554762)
21. Modeling the impact of the 7-valent pneumococcal conjugate vaccine in Chinese infants: an economic analysis of a compulsory vaccination.
Che D; Zhou H; He J; Wu B
BMC Health Serv Res; 2014 Feb; 14():56. PubMed ID: 24507480
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of pneumococcal conjugate vaccination in Georgia.
Komakhidze T; Hoestlandt C; Dolakidze T; Shakhnazarova M; Chlikadze R; Kopaleishvili N; Goginashvili K; Kherkheulidze M; Clark AD; Blau J
Vaccine; 2015 May; 33 Suppl 1():A219-26. PubMed ID: 25919165
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru.
Gomez JA; Tirado JC; Navarro Rojas AA; Castrejon Alba MM; Topachevskyi O
BMC Public Health; 2013 Oct; 13():1025. PubMed ID: 24171921
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru.
Mezones-Holguin E; Canelo-Aybar C; Clark AD; Janusz CB; Jaúregui B; Escobedo-Palza S; Hernandez AV; Vega-Porras D; González M; Fiestas F; Toledo W; Michel F; Suárez VJ
Vaccine; 2015 May; 33 Suppl 1():A154-66. PubMed ID: 25919156
[TBL] [Abstract][Full Text] [Related]
25. Modeling Possible Inclusion of Pneumococcal Conjugate Vaccine into the National Immunization Program for Infants in India.
Ghia C; Wasserman M; Fletcher M; Farkouh R; Rambhad G
Value Health Reg Issues; 2018 May; 15():99-105. PubMed ID: 29655052
[TBL] [Abstract][Full Text] [Related]
26. Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children.
Ayieko P; Griffiths UK; Ndiritu M; Moisi J; Mugoya IK; Kamau T; English M; Scott JA
PLoS One; 2013; 8(6):e67324. PubMed ID: 23826268
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine.
Gouveia M; Jesus G; Inês M; Costa J; Borges M
Hum Vaccin Immunother; 2019; 15(4):850-858. PubMed ID: 30633615
[TBL] [Abstract][Full Text] [Related]
28. Impact of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease and pneumonia in The Gambia: 10 years of population-based surveillance.
; Mackenzie GA; Hill PC; Jeffries DJ; Ndiaye M; Sahito SM; Hossain I; Uchendu U; Ameh D; Adeyemi O; Pathirana J; Olatunji Y; Abatan B; Muhammad BS; Ahameefula E; Fombah AE; Adeshola B; Lobga BG; Saha D; Mackenzie R; Odutola A; Plumb ID; Akano A; Ebruke BE; Ideh RC; Kuti B; Githua P; Olutunde E; Ofordile O; Green E; Usuf E; Badji H; Ikumapayi UN; Manjang A; Salaudeen R; Nsekpong ED; Jarju S; Antonio M; Sambou S; Ceesay L; Lowe-Jallow Y; Fofana S; Jasseh M; Mulholland K; Knoll M; Levine OS; Howie SR; Adegbola RA; Greenwood BM; Corrah T
Lancet Infect Dis; 2021 Sep; 21(9):1293-1302. PubMed ID: 34280357
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong.
Wu DB; Roberts C; Lee VW; Hong LW; Tan KK; Mak V; Lee KK
Hum Vaccin Immunother; 2016; 12(2):403-16. PubMed ID: 26451658
[TBL] [Abstract][Full Text] [Related]
30. Estimating the economic impact of pneumococcal conjugate, Haemophilus influenzae type b and rotavirus vaccines in India: National and state-level analyses.
Constenla D; Liu T
Vaccine; 2019 Dec; 37(52):7547-7559. PubMed ID: 31607600
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of introducing the pneumococcal conjugate vaccine for children under 5 years in the Islamic Republic of Iran.
Ezoji K; Yaghoubi M; Nojomi M; Mahmoody S; Zahraie SM; Moradi-Lakeh M; Tabatabaei SR; Karimi A
East Mediterr Health J; 2019 Nov; 25(10):686-697. PubMed ID: 31774134
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
Cho BH; Stoecker C; Link-Gelles R; Moore MR
Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
[TBL] [Abstract][Full Text] [Related]
33. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
Rozenbaum MH; Sanders EA; van Hoek AJ; Jansen AG; van der Ende A; van den Dobbelsteen G; Rodenburg GD; Hak E; Postma MJ
BMJ; 2010 Jun; 340():c2509. PubMed ID: 20519267
[TBL] [Abstract][Full Text] [Related]
34. Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review.
Saokaew S; Rayanakorn A; Wu DB; Chaiyakunapruk N
Pharmacoeconomics; 2016 Dec; 34(12):1211-1225. PubMed ID: 27510721
[TBL] [Abstract][Full Text] [Related]
35. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.
Shen K; Wasserman M; Liu D; Yang YH; Yang J; Guzauskas GF; Wang BCM; Hilton B; Farkouh R
PLoS One; 2018; 13(7):e0201245. PubMed ID: 30044865
[TBL] [Abstract][Full Text] [Related]
36. Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation.
Shafie AA; Ahmad N; Naidoo J; Foo CY; Wong C; Pugh S; Tan KK
Hum Vaccin Immunother; 2020 Jul; 16(7):1719-1727. PubMed ID: 31951782
[TBL] [Abstract][Full Text] [Related]
37. Impact and cost effectiveness of pneumococcal conjugate vaccine in India.
Krishnamoorthy Y; Eliyas SK; Nair NP; Sakthivel M; Sarveswaran G; Chinnakali P
Vaccine; 2019 Jan; 37(4):623-630. PubMed ID: 30587430
[TBL] [Abstract][Full Text] [Related]
38. Estimating national, regional and provincial cost-effectiveness of introducing childhood 13-valent pneumococcal conjugate vaccination in China: a modelling analysis.
Lai X; Garcia C; Wu D; Knoll MD; Zhang H; Xu T; Jing R; Yin Z; Wahl B; Fang H
Lancet Reg Health West Pac; 2023 Mar; 32():100666. PubMed ID: 36785861
[TBL] [Abstract][Full Text] [Related]
39. Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model.
By A; Sobocki P; Forsgren A; Silfverdal SA
Clin Ther; 2012 Jan; 34(1):177-89. PubMed ID: 22284997
[TBL] [Abstract][Full Text] [Related]
40. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand.
Dilokthornsakul P; Kengkla K; Saokaew S; Permsuwan U; Techasaensiri C; Chotpitayasunondh T; Chaiyakunapruk N
Vaccine; 2019 Jul; 37(32):4551-4560. PubMed ID: 31280944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]